Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium-chloride co-transporter 2 (KCC2), encoded by the SLC12A5 gene, is a member of the SLC12 family of cation-chloride cotransporters. It mediates the coupled export of potassium (K⁺) and chloride (Cl⁻) ions across the plasma membrane, maintaining low intracellular chloride concentrations. This is essential for cell volume regulation and inhibitory neurotransmission mediated by GABA and glycine. Dysfunction or downregulation of KCC2 is implicated in neurological disorders like epilepsy and neuropathic pain.
Inhibition of KCC2 increases intracellular chloride concentration, reducing the hyperpolarizing effect of GABAergic signaling.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium-chloride co-transporter 2 (KCC2).